Big Kahuna statins gobble up bigger share of cholesterol market

Tracy Staton No question, statins are the big gorilla of the cholesterol-fighting drug market. And as Forbes reports today, that drug class is marking out an even ...

A ‘rational’ market finally develops an appetite for biotech IPOs

John Carroll For 5 long years the IPO window on Wall Street has largely been closed to biotech companies. But with investors warming up to the potential rewards after a lengthy chill, ...

Behold the patent cliff: U.S. drug market shrinks for first time

Tracy Staton U.S. drug spending dropped last year. While that may be welcome news for healthcare budgets, it's not so good for branded drugmakers. It may not be so good for patients, ...

U.S. drug market shrinks for first time

John Carroll U.S. drug spending dropped last year. While that may be welcome news for healthcare budgets, it's not so good for branded drugmakers. FierceBiotech News

Behold the patent cliff: U.S. drug market shrinks for first time

Tracy Staton U.S. drug spending dropped last year. While that may be welcome news for healthcare budgets, it's not so good for branded drugmakers. It may not be so good for patients, ...

Teva CEO plans to court Chinese market with generics, respiratory meds

Tracy Staton Teva CEO Jeremy Levin thinks his company and China are a match made in heaven. The Israeli generics giant is, after all, adept at making and selling cheap drugs, which ...

Cipla steamrolls into Enbrel market with biosimilar of Amgen drug

Tracy Staton While the FDA continues its slow-motion release of new guidelines for producing biosimilars in the U.S., India's Cipla has stepped up with a knockoff of the rheumatoid ...

Eli Lilly scores upbeat PhIII data for GLP1 drug in busy diabetes market

Ryan McBride Eli Lilly ($ LLY) has added to a body of positive Phase III data for its once-weekly GLP-1 candidate dulaglutide, with two more late-stage studies that have met their ...

J&J releases more Doxil to the market

Eric Palmer Johnson & Johnson ($ JNJ) and the FDA sprang into action in 2011 when J&J's popular chemo drug Doxil became hard to get because of problems with the contract ...
Page 8 of 8« First...45678
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS